IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Bristol Myers Squibb Co. is a global biopharmaceutical company that discovers, develops, manufactures, licenses, and sells medicines for oncology, hematology, immunology, cardiovascular, neuroscience, and other indications. Its development platforms comprise chemically synthesized or small-molecule drugs, including protein degraders, drugs produced from biological processes, ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Its brand portfolio includes, among others, Opdivo® (nivolumab), Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy), Orencia® (abatacept), Yervoy® (ipilimumab), Reblozyl® (luspatercept-aamt), Breyanzi® (lisocabtagene maraleucel), Eliquis® (apixaban), Revlimid® (lenalidomide), Pomalyst®/Imnovid® (pomalidomide), and Sprycel® (dasatinib). It markets and distributes its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, government agencies, and directly to patients. It maintains facilities in the US, Puerto Rico, the Netherlands, Ireland, and Switzerland. The firm is a Delaware corporation founded in 1887. Its headquarters are located in Princeton, New Jersey.
IBISWorld's SupplierIQ profile covering Bristol-Myers Squibb Company includes financial statements, products & service markets, competitive position and key financial health ratios.
This SupplierIQ profile on Bristol-Myers Squibb Company covers the company’s financial statements, products & service markets, competitive position and key financial health ratios. Bristol-Myers Squibb Company, trading as Bristol-Myers, is a public company with 32.5k employees.
Bristol-Myers Squibb Company primarily operates in Pharmaceutical Preparation Manufacturing, as well as in Natural Disaster & Emergency Relief Services in the US.
The Product & Service Markets chapter provides a breakdown of Bristol-Myers Squibb Company’s key product and service segments, organized by standardized industry classifications like NAICS. It includes their market share in each of these markets with market share trends and insights.
The Competitive Position chapter covers Bristol-Myers Squibb Company’s performance relative to competitors in each of the products and service markets the company operates in. This includes a detailed competitor matrix comparing the market share, return on assets, return on equity, pricing power and competitive outlook. There are qualitative insights and a detailed SWOT analysis included for each product and service market.
The Income Statement chapter includes datasets covering Bristol-Myers Squibb Company’s historical financial performance. Line items include revenue, cost of sales, gross margins, general and administrative costs, research and development costs, depreciation, interest and taxes. This is available in current and historical datasets.
The Balance Sheet chapter includes datasets covering Bristol-Myers Squibb Company’s historical financial health. Current asset and non-current asset accounts include line items like cash, receivables, inventories, property, plant and equipment, investments, goodwill. Current liabilities and non-current liabilities accounts include line items like accounts payable, debts, provisions and lease liabilities. The equity accounts include line items like paid-in capital, retained earnings, employee stock option plans and treasury stock. This is available in current and historical datasets.
The Cash Flows chapter includes detailed line item accounts covering Bristol-Myers Squibb Company’s operating cash flow activities, financing cash flow activities and investing cash flow activities. This is available in current and historical datasets.
The Ratios chapter covers key financial metrics like the operating margin, gross margin, return on equity, return on assets, current ratio, quick ratio, EBIT margins, EBITDA margins, debt ratio, equity ratio and debt to equity ratios. This is available in current and historical datasets.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
According to the 2026 IBISWorld ProcurementIQ report, Bristol-Myers Squibb Company generated $48.2bn in revenue.
The 2026 ProcurementIQ report benchmarks Bristol-Myers Squibb Company against its top competitors across execution score, operational capabilities, pricing power, and market share.
Bristol-Myers Squibb Company’s EBITDA margin is reported across a 7-year period in the 2026 IBISWorld ProcurementIQ report. The report includes a full income statement breakdown.
The 2026 report identifies all NAICS-coded product and service markets Bristol-Myers Squibb Company participates in, including market share, concentration, profitability trends, and average vendor risk ratings.
The 2026 ProcurementIQ report lists Bristol-Myers Squibb Company’s employee count and benchmarks workforce size against key competitors to assess relative operational capacity.